Wockhardt on August 9 said its net loss narrowed to Rs 16 crore for the quarter ended June 30, 2024 as against Rs 136 crore in the year-ago period. On back of strong quarterly numbers, Wockhardt's shares on BSE rose 5 percent on August 9.
The biotech major said that it registered total income at Rs 769 crore for the first quarter as compared to Rs 658 crore in the year-ago period.
The drugmaker, which is planning to complete Phase III trials for Zaynich, will now focus on anti-bacterial drugs under its new discovery project.
The company said it is the only pharma entity in the world to get the US FDA’s QIDP Status (Qualified Infectious Disease Product) in six of its anti-bacterial discovery programmes. These specifically target the menace of superbugs.
In a separate stock filing, the company also confirmed the appointment of Paresh Kajrolkar as internal auditor. Kajrolkar joins in place of Prasanna Bharatan, who had stepped down from the post last month.
On August 9, Wockhardt's shares on NSE closed trading 5 percent higher at Rs 967.90 apiece.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
